In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Pharmaceutical
A ground-breaking oral treatment that could increase survival by 10 months has been given the green light for patients with incurable blood cancer in England and Wales. 18 January 2023
Pharmaceutical
In the USA, the National Institute of Allergy and Infectious Diseases (NIAID) has awarded $5.5 million to the Blumberg Institute to research treatments for yellow fever. 18 January 2023
Pharmaceutical
Cost-effectiveness body the Institute for Clinical and Economic Review (ICER) has published its second annual Barriers to Fair Access assessment of prescription drug coverage policies in the USA. 18 January 2023
Pharmaceutical
Sygnature Discovery, which claims to be the UK’s largest independent drug discovery expert and research partner, revealed that it has acquired Scotland-based SB Drug Discovery, a provider of ion channel and receptor drug discovery research delivering cell line generation and compound screening solutions in neuroscience and other therapeutic indications. 18 January 2023
Biotechnology
Phase III success for Moderna will help the company catch up with rivals GSK and Pfizer in the upcoming battle to treat respiratory syncytial virus (RSV) infections. 18 January 2023
Pharmaceutical
French pharma major Sanofi revealed late yesterday that the US Food and Drug Administration (FDA) has approved its Adacel (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed) during the third trimester of pregnancy to help protect against pertussis, or whooping cough, in infants younger than two months of age. 18 January 2023
Biotechnology
Privately-held US cancer drug biotech Elicio Therapeutics has entered into a definitive merger agreement with Angion Biomedica under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction. 18 January 2023
Pharmaceutical
Ohio, USA-based 46brooklyn Research - a non-profit corporation that seeks to improve the accessibility and usability of US drug pricing data - has delivered its latest report on what Americans are paying for their medicines. 17 January 2023
Biotechnology
Spanish plasma-derived medicines specialist Grifols has announced that its plasma-protein based fibrin sealant (FS) for controlling surgical bleeding obtained positive top-line results from a Phase IIIb clinical trial in pediatric patients. 17 January 2023
Biotechnology
Cambridge, Massachusetts-based oncology specialist Leap Therapeutics has bought the privately-owned company Flame Biosciences. 17 January 2023
Biotechnology
Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today announced the appointment of Susan Kalled, as chief scientific officer. 17 January 2023
Biotechnology
The European Parliament’s COVI committee has voted to ban officials from US pharma giant Pfizer from attending sessions. 17 January 2023
Biotechnology
CAR-T cell therapy specialist CARsgen Therapeutics has inked a deal with a division of Huadong Medicine for the commercialization of CT053 in China. 17 January 2023
Biotechnology
California, USA-based clinical-stage biopharmaceutical company 89bio’s pegazofermin has potential to become one of the major players in the dyslipidemia space if it is successful in Phase III clinical trials, says analyst. 17 January 2023
Biosimilars
Adding to European Commission clearance in November last year, German drugmaker STADA Arzneimittel and Sweden’s Xbrane Biopharma announced that their Ximluci (ranibizumab), a biosimilar referencing Lucentis, has been granted marketing authorization by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). 17 January 2023
Biotechnology
Rachel Abbott has been appointed chief scientific officer of Pan Cancer T, a biotech spin-off from the Erasmus University Medical Center, in the Netherlands. 17 January 2023
Pharmaceutical
In contrast to overall UK pharma industry claims of falling R&D in the country, the Cell and Gene Therapy Catapult (CGT Catapult) reports the opposite. 17 January 2023
Pharmaceutical
The trade group representing the UK pharmaceutical industry has published a report highlighting significant variation in access to innovative medicines in the country. 17 January 2023
Biotechnology
Following the controversial approval and dismal launch of their first Alzheimer’s drug, Aduhelm (aducanumab), expectations for Eisai and Biogen’s follow on treatment are mixed, given that their anti-amyloid beta (Aβ) monoclonal antibody (MAb), Leqembi (lecanemab) gained approval from the Food and Drug Administration (FDA) under the accelerated approval pathway for the treatment of Alzheimer’s disease (AD) in patients with early AD. 17 January 2023
Generics
India's interim free trade agreement with Australia is set to offer a significant relaxation of factory inspections, which could pave the way for many more commercial deals with developed countries, according to Pharmexcil, India's pharmaceutical export promotion council. 16 January 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze